期刊文献+

重组人组织型纤溶酶原激活剂改构体的表达、复性与分离纯化 被引量:2

Study on expression, renaturation and purification of reteplase
下载PDF
导出
摘要 目的 获得具有高纯度、高生物活性的重组人组织型纤溶酶原激活剂改构体(瑞替普酶,reteplase,r-PA)。方法 reteplase基因克隆到表达质粒pJZ-100中,转化Escherichia cli B121(DE3),在0.05 mmol·L-1异丙基硫代-β-D-半乳糖苷(IPTG)诱导下获得高效表达,表达产物通过脉冲稀释法复性,复性后的蛋白质用ETI-Sepharose 4B亲和色谱纯化。结果 表达产物占菌体总蛋白质的20%,脉冲稀释法复性后复性收率为28%,经纯化后纯度达96%以上,比活为580 000 IU·mg-1。结论 建立了reteplase表达、复性与纯化工艺,以此工艺可获得高活性高纯度的reteplase。 OBJECTIVE: To obtain the recombinant human tissue-type plasminogen activator mutant(reteplase, r-PA) with high purity and high specific activity. METHODS: Reteplase sequence was cloned into pJZ-100 expression vector. Being induced by IPTG, reteplase was highly expressed in Escherichia coli BL21 (DE3). The activity of expressed protein was recovered by step-wise dilution in vitro. The reteplase was purified by affinity chromatography. RESULTS: Expressed reteplase constituted more than 20% of total bacterial protein. The activity recovery by step-wise dilution was 28%. After purification, the purity of reteplase was above 96% and its specific activity was 580 000 IU&middot mg -1. CONCLUSION: The method of reteplase expression, renaturation and purification was established. The process can be a scheme to obtain reteplase with high purity and the high activity from E. coli.
出处 《中国药学杂志》 EI CAS CSCD 北大核心 2004年第7期550-552,557,共4页 Chinese Pharmaceutical Journal
关键词 重组人组织型纤溶酶原激活剂改构体 表达 复性 纯化 Cloning Escherichia coli Mutagenesis Purification Tissue
  • 相关文献

参考文献8

  • 1Dewood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocarbal rafarction[J]. N Engl J Med, 1980, 303:897.
  • 2Pennica D, Holmes WE, Kohr WJ, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli [J]. Nature, 1983, 301:214.
  • 3Seifried E, Muller MM, Martin U, et al. Application of a novel recombinant plasminogen activator in acute myocardial infarction patients: pharmacokinetics and effects on the hemostatic system [J].Ann N Y Acad Sci, 1992,667(12):417.
  • 4Bode C, Smalling RW, Sen S, et al. Reconbinant plasminogen activator angiographic phase Ⅱ international dose finding study(RAPID):patency analysis and mortality endpoints[J]. Circulation, 1993, 88(4, Part2): 1562.
  • 5Bradford MB. A rapid and senditive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding[J]. Annl Biochem, 1976,72:248.
  • 6Sambrook J, Fritsch EF, Maniatis T. Molecular Clonirng a Laboratory Manual[M]. 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989,880-887.
  • 7Rudolph R, Fischer S. Process for obtaining renatured proteins[P].United States Patent, 4.933.434 . 1990-06-12.
  • 8陈黄实,任启生,宋新荣,黄子才.刺桐属胰蛋白酶抑制剂的结构与生物活性关系[J].生物技术通讯,2002,13(3):222-225. 被引量:7

二级参考文献36

  • 1Joubert FJ. Proteinase inhibitors from Erythrina lysistemon seed [J]. Phytochemistry, 1982,21:1213
  • 2Joubert FJ. Proteinase inhibitors from Erythrina abyssinnica and Erythrina decora seed[J]. S Afr J Chem, 1986,39:169
  • 3Joubert FJ,Carlsson FHH and Haylett T. Purification and some properties of two proteinase inhibitors (DE-1 andDE-3) from Erythrina latissima seed Hoppe-Seyler's Z [J]. Physiol Chem, 1981,362:531
  • 4Jouber FJ, Heussen C and Dowdle EBD. The Complete amino acid sequence of trypsin inhibitor DE-3 from Erythrina latissima seeds[J]. J Biol Chem, 1985,260:12948
  • 5Jouber FJ and Sharon N. Proteinase inhibitors from Erythrina corallodendron and Erythrina cristagalli seeds[J]. Phytochemistry,1985,24:1169
  • 6Heussen C, Joubert F and Dowdle EB. Purification of human tissue plasminogen activator with Erythrina trypsin inhibitor[J]. J Biol Chem, 1984,259:11635
  • 7Francois J, Joubet EH. The reactive sites inhibitrosfrom Erythrina seeds[J]. Int J Biochem, 1987,1
  • 8Kohnert V,Rvdolph R, Verheijen JH, et al. Biocoperties of the Kringle 2 and protease domains are inthe refolded t-Pa deletion variant BM 06.022[J]. Protein Eng. 1992,5:93
  • 9Leuag D, Abbenante G and David PF. Protease inhibitors: cur rent status and future prospects [J]. J Medicinal Chemistry, 2000,43(3):305
  • 10Christa HS, Edwn HM and Eugene BDD. The Erythrina protease inhibitor: interactions with tisue plasminogen activator [J].Thrombsis and Haemostasis, 1991,66(2):226

共引文献7

同被引文献39

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部